StreetInsider.com News Articles

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Wed, 05 Aug 2026 09:00:00 -0400

As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi^® and Canalevia^®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications

Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Wed, 05 Aug 2026 09:00:00 -0400

As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi^® and Canalevia^®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications
Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight

Form DEF 14A Jaguar Health, Inc. For: Sep 04

Mon, 03 Aug 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260803/26858693.html

Form DEF 14A Jaguar Health, Inc. For: Sep 04

Mon, 03 Aug 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260803/26858693.html

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

Tue, 28 Jul 2026 09:00:00 -0400

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy

SAN FRANCISCO, CA / ACCESS Newswire / July 28, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the findings of exploratory surveys of dog owners and veterinary oncologists support the company's commercial opportunity for Neonorm Dog, a new extension of Jaguar's

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

Tue, 28 Jul 2026 09:00:00 -0400

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy

SAN FRANCISCO, CA / ACCESS Newswire / July 28, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the findings of exploratory surveys of dog owners and veterinary oncologists support the company's commercial opportunity for Neonorm Dog, a new extension of Jaguar's

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260727/26816385.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:01:00 -0400
si-local-file:///var/storage/secattach/20260727/26816385.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:00:00 -0400
si-local-file:///var/storage/secattach/20260727/26816333.html

Form 424B3 Jaguar Health, Inc.

Mon, 27 Jul 2026 08:00:00 -0400
si-local-file:///var/storage/secattach/20260727/26816333.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260727/26815425.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260727/26815425.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260727/26815427.html

Form EFFECT Jaguar Health, Inc.

Mon, 27 Jul 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260727/26815427.html

Form PRE 14A Jaguar Health, Inc. For: Sep 04

Fri, 24 Jul 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260724/26813710.html

Form PRE 14A Jaguar Health, Inc. For: Sep 04

Fri, 24 Jul 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260724/26813710.html

Jaguar Health (JAGX) files for 41M share offering by selling stockholders

Fri, 24 Jul 2026 14:01:27 -0400

Jaguar Health (NASDAQ: JAGX) filed for up to 41,000,000 share offering by selling stockholders.

Jaguar Health (JAGX) files for 41M share offering by selling stockholders

Fri, 24 Jul 2026 14:01:27 -0400

Jaguar Health (NASDAQ: JAGX) filed for up to 41,000,000 share offering by selling stockholders.

Form S-1/A Jaguar Health, Inc.

Fri, 24 Jul 2026 13:59:00 -0400
si-local-file:///var/storage/secattach/20260724/26812918.html

Form S-1/A Jaguar Health, Inc.

Fri, 24 Jul 2026 13:59:00 -0400
si-local-file:///var/storage/secattach/20260724/26812918.html

Jaguar Health expands crofelemer compassionate use to EU infant

Wed, 22 Jul 2026 09:01:55 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an infant in the European Union under a compassionate use pathway for the treatment of intestinal failure due to microvillus inclusion disease (MVID).
Napo has previously supplied crofelemer to infant and pediatric patients with MVID in the U.S. under Single-Patient Investigational New Drug applications, and has also provided the drug for an investigator-initiated proof-of-concept trial in pediatric patients in the United Arab Emirates.
According to the company, the EU patient's physician became aware of crofelemer following data presentations at the 58th Annual European

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Wed, 22 Jul 2026 09:00:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID

SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union (EU) for compassionate use.
As

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Wed, 22 Jul 2026 09:00:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID

SAN FRANCISCO, CA / ACCESS Newswire / July 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union (EU) for compassionate use.
As

Jaguar Health (JAGX) files for 5.52M share offering by selling stockholders

Thu, 16 Jul 2026 06:04:16 -0400

Jaguar Health (NASDAQ: JAGX) has filed for up to 5,522,551 share offering by selling stockholders.

Jaguar Health (JAGX) files for 5.52M share offering by selling stockholders

Thu, 16 Jul 2026 06:04:16 -0400

Jaguar Health (NASDAQ: JAGX) has filed for up to 5,522,551 share offering by selling stockholders.